[P‐185]: Estrogen receptor beta selective ligands for prevention of neurodegeneration: From in silico screening to at bench bioanalysis

of A 12-28P in AD Tg model mice. Methods: Female APP/ PS1 Tg AD mice were treated with A 12-28P (1mg of peptide or placebo administered intraperitoneally) for five months starting from the age of two months, which is prior to the onset of detectable brain amyloid deposits. Conclusions: Treatment with A 12-28P resulted in a significant reduction of A load: 51.6% in the neocortex, 40.0% in the hippocampus, and 49.2% in the cingulate/retropslenial cortex (p 0.01). Fibrillar A , detected by Thioflavin-S staining, was reduced by 21.9%, 24.7%, and 28.9%, respectively (p 0.05). Levels of formic acid extracted A 1-40 and A 1-42 were decreased on ELISA measurements by 42.5% and 29.9%, respectively (p 0.01). No signs of toxicity or any autoimmune reaction were observed in treated animals. These results demonstrate that pharmacological blocking of the apoE/A interaction may be used to prevent A deposition in AD patients.